Beaird Harris Wealth Management LLC Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Beaird Harris Wealth Management LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,501 shares of the company’s stock after selling 271 shares during the period. Beaird Harris Wealth Management LLC’s holdings in Johnson & Johnson were worth $405,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of JNJ. International Assets Investment Management LLC lifted its position in Johnson & Johnson by 20,130.0% during the third quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock valued at $559,832,000 after purchasing an additional 3,437,397 shares in the last quarter. Marshall Wace LLP boosted its position in shares of Johnson & Johnson by 506.9% in the second quarter. Marshall Wace LLP now owns 3,884,962 shares of the company’s stock worth $567,826,000 after purchasing an additional 3,244,862 shares during the period. Ninety One UK Ltd raised its position in shares of Johnson & Johnson by 59.0% during the 2nd quarter. Ninety One UK Ltd now owns 6,708,943 shares of the company’s stock valued at $980,579,000 after purchasing an additional 2,489,925 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Johnson & Johnson by 228.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after buying an additional 2,356,359 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Johnson & Johnson by 10.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 18,780,645 shares of the company’s stock worth $2,744,979,000 after buying an additional 1,831,751 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.3 %

Shares of NYSE:JNJ opened at $146.23 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business has a 50 day simple moving average of $157.01 and a two-hundred day simple moving average of $156.28. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The firm has a market capitalization of $352.07 billion, a PE ratio of 21.16, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.66 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th were paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. The ex-dividend date was Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wolfe Research assumed coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Royal Bank of Canada lifted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Bank of America reaffirmed a “neutral” rating and issued a $166.00 price objective on shares of Johnson & Johnson in a research note on Tuesday. Finally, Guggenheim raised their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.73.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.